SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-086111
Filing Date
2024-07-24
Accepted
2024-07-24 17:00:23
Documents
58
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q vktx-20240630.htm   iXBRL 10-Q 2081882
2 EX-10.1 vktx-ex10_1.htm EX-10.1 649109
3 EX-10.2 vktx-ex10_2.htm EX-10.2 58346
4 EX-10.3 vktx-ex10_3.htm EX-10.3 158628
5 EX-31.1 vktx-ex31_1.htm EX-31.1 16113
6 EX-31.2 vktx-ex31_2.htm EX-31.2 16089
7 EX-32.1 vktx-ex32_1.htm EX-32.1 11877
  Complete submission text file 0000950170-24-086111.txt   9107853

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT vktx-20240630.xsd EX-101.SCH 1065008
60 EXTRACTED XBRL INSTANCE DOCUMENT vktx-20240630_htm.xml XML 1415710
Mailing Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121
Business Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121 858-704-4660
Viking Therapeutics, Inc. (Filer) CIK: 0001607678 (see all company filings)

IRS No.: 461073877 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37355 | Film No.: 241138852
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)